Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Equity Ratio (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Equity Ratio for 6 consecutive years, with 0.88 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 49.19% year-over-year to 0.88, compared with a TTM value of 0.88 through Dec 2025, up 49.19%, and an annual FY2025 reading of 0.88, up 49.19% over the prior year.
  • Equity Ratio was 0.88 for Q4 2025 at SAB Biotherapeutics, down from 0.9 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.9 in Q3 2025 and bottomed at 0.3 in Q3 2021.
  • Average Equity Ratio over 5 years is 0.59, with a median of 0.59 recorded in 2022.
  • The sharpest move saw Equity Ratio surged 94.41% in 2022, then plummeted 46.48% in 2025.
  • Year by year, Equity Ratio stood at 0.48 in 2021, then grew by 28.42% to 0.61 in 2022, then rose by 11.88% to 0.68 in 2023, then fell by 13.92% to 0.59 in 2024, then soared by 49.19% to 0.88 in 2025.
  • Business Quant data shows Equity Ratio for SABS at 0.88 in Q4 2025, 0.9 in Q3 2025, and 0.4 in Q2 2025.